Reply

We appreciate the comments offered by Dr Friesen in response to our study examining the impact of age and CYP2C19 genotype on the pharmacokinetics of pantoprazole in pediatric patients who are obese.1 Dr Friesen is correct in that our study cohort did not include a group of children who were not obese. Consequently, any comparisons that we offered carried the caveat of having used a historical cohort for comparison.

https://ift.tt/2HJfiol